Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and Safety of Insulin Degludec/Insulin Aspart BID vs Insulin Degludec OD + Insulin Aspart in Type 2 Diabetes
NCT01713530Phase 3Completed
- Sponsor
- Novo Nordisk
- Start
- Feb 2013
- Primary completion
- Jan 2014
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 5
01
Overview
A Phase 3 trial of insulin degludec + insulin aspart in type 2 diabetes mellitus (T2DM), sponsored by Novo Nordisk. Started Feb 2013; status: completed.
02
Drugs
insulin degludec + insulin aspart
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT01713530.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01713530.